Fresenius Kabi Breaks Ground on $250-Million Facility Expansion

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-10-04-2017
Volume 12
Issue 10

Fresenius Kabi broke ground on a previously announced $250 million expansion of its Melrose Park, IL, manufacturing facility.

On Sep. 21, 2017, Fresenius Kabi, a German specialty and generic pharmaceuticals company and a subsidiary of Fresenius SE & Co. KGaA, broke ground on a $250-million expansion of its Melrose Park, IL manufacturing facility. The site, announced in August 2016, will facilitate the aseptic manufacturing of generic injectable medicines. The expansion of the facility will include several new buildings, with completion expected by 2026.

This investment is part of a recent series of business endeavors by the company. In April 2017, the company publicized an agreement to acquire Akorn, a US-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for $34 per share, equivalent to $4.3 billion, plus approximately $450 million of net debt. During that time, the company also announced plans to acquire Merck KGaA’s biosimilars business, which closed in September 2017, for the purchase price of EUR 656 million (US$769 million).

Source: Fresenius Kabi 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content